Low dose linomide in Type I juvenile diabetes of recent onset:: a randomised placebo-controlled double blind trial

被引:64
作者
Coutant, R
Landais, P
Rosilio, M
Johnsen, C
Lahlou, N
Chatelain, P
Carel, JC
Ludvigsson, J
Boitard, C
Bougnères, PF
机构
[1] Hop St Vincent de Paul, Serv Endocrinol Pediat, Dept Paediat Endocrinol, F-75014 Paris, France
[2] Hop Necker Enfants Malad, Dept Biostat, Paris, France
[3] Pharmacia, Lund, Sweden
[4] Debrousse Hosp, Dept Paediat Endocrinol, Lyon, France
[5] Univ Hosp, Div Pediat, Linkoping, Sweden
关键词
linomide; Type I diabetes;
D O I
10.1007/s001250051028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The quinoline-3-carboxamide, linomide, protects non-obese diabetic mice from diabetes. The effects of linomide on insulin needs and beta cell function were studied in recent juvenile Type I diabetes in a double-blind trial. Patients with recent onset diabetes were randomly assigned to treatment with a fixed dose of 2.5 mg linomide (42 patients) or placebo (21 patients) for 1 year, in addition to insulin and diet. Glycated haemoglobin was 10-15% lower at 9 months (p = 0.003) and 12 months (p < 0.05) in the linomide group. The insulin dose was 32-40% smaller in the linomide group at 3 (p < 0.03), 6 (p < 0.02), 9 (p < 0.001) and 12 months (p = 0.01). Insulin doses correlated negatively with C peptide values (p = 0.001-0.002). The trend for higher C peptide values in the linomide group did not reach significance. In a post hoc subgroup analysis performed in 40 patients (25 from the linomide group and 15 from the placebo group) who still had detectable residual beta cell function at entry, linomide was associated with 45-59% higher C peptide value at 6 months (p < 0.05), 9 months 01 < 0.05) and 12 months (p < 0.05). The main adverse effects of linomide were mild transitory anaemia (45 vs 10 % in the linomide and placebo groups), thrombocytopenia (21 vs 10%), and mild joint discomfort (45 vs 5%) with no clinical signs. In conclusion, low-dose linomide reduced the insulin needs in patients with juvenile Type I diabetes of recent onset and improved beta cell function in patients who still had detectable beta cell function at entry. These results support further clinical and experimental studies to define the effects of linomide in Type I diabetes provided the safety of linomide is reliably established.
引用
收藏
页码:1040 / 1046
页数:7
相关论文
共 44 条
[1]   Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis [J].
Andersen, O ;
Lycke, J ;
Tollesson, PO ;
Svenningsson, A ;
Runmarker, B ;
Linde, AS ;
Astrom, M ;
Gjorstrup, P ;
Ekholm, S .
NEUROLOGY, 1996, 47 (04) :895-900
[2]  
[Anonymous], 1988, Diabetes, V37, P1574
[3]  
ASSAN R, 1985, LANCET, V1, P67
[4]   STIMULATION OF NK CELL, T-CELL, AND MONOCYTE FUNCTIONS BY THE NOVEL IMMUNOMODULATOR LINOMIDE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION - A PILOT-STUDY IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA [J].
BENGTSSON, M ;
SIMONSSON, B ;
CARLSSON, K ;
NILSSON, B ;
SMEDMYR, B ;
TERMANDER, B ;
OBERG, G ;
TOTTERMAN, TH .
TRANSPLANTATION, 1992, 53 (04) :882-888
[5]  
BERGH J, 1989, 5 ECCO M LOND SEPT 3
[6]  
BJORK J, 1989, AGENTS ACTIONS, V27, P319
[7]   IMPROVEMENT OF DIABETIC CONTROL AND ACCEPTABILITY OF A 3-INJECTION INSULIN REGIMEN IN DIABETIC ADOLESCENTS - A MULTICENTER CONTROLLED-STUDY [J].
BOUGNERES, PF ;
LANDAIS, P ;
MAIRESSE, AM ;
JAIS, JP ;
JOS, J ;
PEYRAUD, J ;
WIELICZKO, MC ;
CHAVOIX, P ;
GARANDEAU, P ;
ASENSI, D ;
YTHIER, H ;
ROULAND, V ;
MAZOYER, T ;
LETURCQ, F ;
RAYNAUD, E .
DIABETES CARE, 1993, 16 (01) :94-102
[8]   FACTORS ASSOCIATED WITH EARLY REMISSION OF TYPE-I DIABETES IN CHILDREN TREATED WITH CYCLOSPORINE [J].
BOUGNERES, PF ;
CAREL, JC ;
CASTANO, L ;
BOITARD, C ;
GARDIN, JP ;
LANDAIS, P ;
HORS, J ;
MIHATSCH, MJ ;
PAILLARD, M ;
CHAUSSAIN, JL ;
BACH, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (11) :663-670
[9]   LIMITED DURATION OF REMISSION OF INSULIN DEPENDENCY IN CHILDREN WITH RECENT OVERT TYPE-I DIABETES TREATED WITH LOW-DOSE CYCLOSPORINE [J].
BOUGNERES, PF ;
LANDAIS, P ;
BOISSON, C ;
CAREL, JC ;
FRAMENT, N ;
BOITARD, C ;
CHAUSSAIN, JL ;
BACH, JF .
DIABETES, 1990, 39 (10) :1264-1272
[10]   AGE-DEPENDENT HLA GENETIC-HETEROGENEITY OF TYPE-1 INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CAILLATZUCMAN, S ;
GARCHON, HJ ;
TIMSIT, J ;
ASSAN, R ;
BOITARD, C ;
DJILALISAIAH, I ;
BOUGNERES, P ;
BACH, JF .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2242-2250